Inclusion Criteria:

• Adult subjects (18-75 years of age) with either HBeAg positive or HBeAg negative CHB prior to transplant
• Willing and able to provide written informed consent
• Subjects with detectable anti-HBs (by a local laboratory result within 30 days of screening)
• Subjects must be stable and may not have 2 or more of the following laboratory parameters associated with decompensated liver disease: e.g., conjugated bilirubin >1.5 X ULN, PT > 1.5 X ULN, platelets < 60,000/mm3, serum albumin < 3.0 g/dL
• Must have had at least 12 weeks of center specific prophylactic therapy including HBIG post-transplant
• Calculated creatinine clearance (CLcr) >= 40 mL/min using the Cockcroft- Gault equation
• No significant evidence of ongoing deterioration of renal function.
• Negative serum beta-HCG (for females of childbearing potential only)

Exclusion Criteria:

• Subjects with CHB recurrence, i.e., confirmed HBV DNA >= 400 copies/mL, post liver transplant
• Pregnant women, women who are breast feeding or who believe they may wish to become pregnant during the course of the study.
• Males and females of reproductive potential who are unwilling to use an "effective" method of contraception during the study and for at least 30 days from the date of last dose of study drug.
• Evidence of hepatocellular carcinoma (HCC), e.g., alpha-fetoprotein > 50 ng/mL or by any other standard of care measure or presence of multifocal HCC at the time of transplantation
• Prior tenofovir DF or emtricitabine/tenofovir DF experience post-transplant or > 12 months treatment with tenofovir DF or emtricitabine/tenofovir DF treatment pre transplant
• Co infection with HCV (by serology), HIV, or HDV pre-transplant or at screening.
• Significant renal, cardiovascular, pulmonary, or neurological disease.
• Known hypersensitivity to the study drugs, the metabolites or formulation excipients
• Likely to receive systemic drugs with nephrotoxic potential, except immunosuppressive agents (e.g., cyclosporine, tacrolimus), during the course of the study.
• History of variceal bleeding or hepatic encephalopathy post OLT